CAPR Capricor Therapeutics, Inc.
USHealthcareAs of 2026-07-09 11:48
Why CAPR matters now
Capricor Therapeutics, Inc. (CAPR) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.90 with -1.57% on the session and $1.00B in market capitalization; recent performance reads 1-month +5.42% and YTD -1.66%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-33.9M, and EPS of $-0.59. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.8%.
The latest indexable market news headline is "What's Going On With Capricor Therapeutics Stock On Friday?" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $50.00; recent insider activity includes Maurer Michael T filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.85
P/S
0.00
EV/EBITDA
1.36
DCF Value
$5.77
FCF Yield
-8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.3%
ROA
-35.1%
ROIC
-40.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-33.9M | $-0.59 |
| Q4 2025 | $0.00 | $-30.2M | $-0.62 |
| FY 2025 | $0.00 | $-105.0M | $-2.26 |
| Q3 2025 | $0.00 | $-24.6M | $-0.54 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$50.00
Target (Median)
$50.00
Target Range
$38.00 - $62.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.37
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.